Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated radiation therapy (IMRT) in high-risk prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 4, 2012, Pages

  Vuky, Jacqueline ^a   Pham, Huong T ^b   Warren, Sarah ^c   Douglass, Erika ^c   Badiozamani, Kasra ^b   Madsen, Berit ^d   Hsi, Alex ^d   Song, Guobin ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b VIRGINIA MASON MEDICAL CENTER   (United States)

^c BENAROYA RESEARCH INSTITUTE   (United States)

^d Peninsula Cancer Center   (United States)

Author keywords

Bevacizumab; Hormonal therapy; Prostate cancer; Radiation therapy

Indexed keywords

ACUTE TOXICITY; ANDROGEN SUPPRESSION; BEVACIZUMAB; BICALUTAMIDE; GLEASON SCORES; GOSERELIN; HORMONAL THERAPY; HYPONATREMIA; INTENSITY-MODULATED RADIATION THERAPY; LEUCOPENIA; LOCALIZED PROSTATE CANCER; PELVIC LYMPH NODES; PHASE II; PRE-TREATMENT; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; SEMINAL VESICLE; URINARY RETENTION;

ANTIGENS; DISEASES; PATIENT TREATMENT; RADIOTHERAPY; TOXICITY; UROLOGY;

PHYSICAL THERAPY;

BEVACIZUMAB; BICALUTAMIDE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTERIAL THROMBOEMBOLISM; ARTHRALGIA; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CLINICAL ARTICLE; CONFUSION; CYSTITIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; EPISTAXIS; FATIGUE; FOLLOW UP; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL PAIN; GASTROINTESTINAL TOXICITY; GENITOURINARY TOXICITY; GLEASON SCORE; HEADACHE; HEMATOCHEZIA; HEMATURIA; HEMORRHOID; HIGH RISK PATIENT; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPONATREMIA; INCONTINENCE; INTENSITY MODULATED RADIATION THERAPY; LEUKOPENIA; LIBIDO DISORDER; LONG TERM CARE; LYMPHOCYTOPENIA; MALE; ORAL BLEEDING; PAIN; PELVIS LYMPH NODE; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROCTITIS; PROSTATE ADENOCARCINOMA; PROSTATITIS; PROTEINURIA; RADIATION CYSTITIS; RADIATION DOSE; RADIATION INJURY; RADIATION PROCTITIS; RASH; RECTUM HEMORRHAGE; RECTUM PAIN; SEMINAL VESICLE; SIDE EFFECT; THROMBOEMBOLISM; URETHRAL PAIN; URINARY FREQUENCY; URINE RETENTION; UROGENITAL TRACT DISEASE; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; GOSERELIN; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NITRILES; PILOT PROJECTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; RISK; TOSYL COMPOUNDS;

EID: 84857914151     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.09.002     Document Type: Article

References (30)

1. T.M. Pisansky, M.J. Kahn, and D.G. Bostwick An enhanced prognostic system for clinically localized carcinoma of the prostate Cancer 79 1997 2154 2161
2. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer J Clin Oncol 17 1999 168 173
3. M. Bolla, L. Collette, and G. Van Tienhoven Ten year results of long term adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: A phase III EORTC study Int J Radiat Oncol Biol Phys 72 2008 s30
4. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial Lancet 360 9327 2002 103 106
5. G.E. Hanks, T.F. Pajak, and A. Porter Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02 J Clin Oncol 21 2003 3972 3978
6. M.J. Zelefsky, Z. Fuks, and M. Hunt High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients Int J Radiat Oncol Biol Phys 53 2002 1111 1116
7. M.J. Zelefsky, Z. Fuks, and M. Hunt High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer J Urol 166 2001 876 881
8. M.S. Khil, J.H. Kim, and L.J. Bricker Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy Cancer J Sci Am 3 1997 289 296
9. S.A. Rosenthal, B. Kyoungwha, and K.J. Pienta Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: Preliminary toxicity analysis of RTOG 99-02 Int J Radiat Oncol Biol Phys 73 2009 672 678
10. J.A. Jiménez, C. Kao, and S. Raikwar Current status of anti-angiogenesis therapy for prostate cancer Urol Oncol 24 2006 260 268
11. R. Vergis, C.M. Corbishley, and A.R. Norman Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: A retrospective analysis of two randomised radiotherapy trials and one surgical cohort study Lancet Oncol 9 2008 342 351
12. K.A. Lyseng-Williamson, and D.M. Robinson Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer BioDrugs 20 2006 193 195
13. C.G. Lee, M. Heijn, and E. di Tomaso Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions Cancer Res 60 2000 5565 5570
14. D.H. Gorski, H.J. Mauceri, and R.M. Salloum Prolonged treatment with angiostatin reduces metastatic burden during radiation therapy Cancer Res 63 2003 308 311
15. S.V. Kozin, Y. Boucher, and D.J. Hicklin Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts Cancer Res 61 2001 39 44
16. L. Geng, E. Donnelly, and G. McMahon Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy Cancer Res 61 2001 2413 2419
17. M. Roach III, G. Hanks, and H. Thames Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix consensus conference J Radiat Oncol Biol Phys 65 2006 965 974
18. B.L. Madsen, R.A. Hsi, and H.T. Pham Intrafractional stability of the prostate using a stereotactic radiotherapy technique J Radiat Oncol Biol Phys 57 2003 1285 1291
19. P. Kupelian, T. Willoughby, and A. Mahadevan Multi-institutional clinical experience with the Calypso system in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy Int J Radiat Oncol Biol Phys 67 2007 1088 1098
20. W.K. Kelly, S. Halabi, and M.A. Carducci A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401 [Abstract] J Clin Oncol 28 Suppl. 2010 18s
21. K.S. Basu, A. Bahl, and V. Subramani Normal tissue complication probability: Does simultaneous integrated boost intensity-modulated radiotherapy score over other techniques in treatment of prostate adenocarcinoma J Cancer Res Ther 5 2009 78 84
22. A. Pollack, A.L. Hanlon, and E.M. Horwitz Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose Int J Radiat Oncol Biol Phys 64 2006 518 526
23. P.A. Kupelian, T.R. Willoughby, and C.A. Reddy Hypofractionated intensity modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic Experience Int J Radiat Oncol Biol Phys 68 2007 1424 1430
24. J.M. Michalski, K. Winter, and J.A. Purdy Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose level V Int J Radiat Oncol Biol Phys 62 2005 706 713
25. F. Eskens, and J. Verweij The clinical toxicity profile of vascular endothelial factor (VEGF) and vascular endothelial factor receptor (VEGFR) targeting angiogenesis inhibitors Eur J Cancer 42 2006 3127 3139
26. Crane CH, Ellis LM, Xiong H, et al. Preliminary results of a phase I study of rhuMab VEGF (bevacizumab) with concurrent radiotherapy (XRT) and capecitabine (CAP) [Abstract]. Presented at the January 2004 Gastrointestinal Cancers Symposium in San Francisco, CA.
27. F. Winkler, S.V. Kozin, and R.T. Tong Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoeitin-1 and matrix metalloproteinases Cancer Cell 6 2004 553 563
28. R.T. Tong, Y. Boucher, and S.V. Kozin Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors Cancer Res 64 2004 3731 3736
29. F. Yuan, Y. Chen, and M. Dellian Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor vascular permeability factor antibody Proc Natl Acad Sci U S A 93 1996 14765 14770
30. R.P.M. Dings, M. Loren, and H. Heun Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization Clin Cancer Res 13 2007 3395 3402